Hyperthermic laser treatment from Cynosure receives expanded FDA clearance

July 10, 2015

Cynosure has received FDA approval for its hyperthermic laser treatment for noninvasive lipolysis of the abdomen.

Aesthetic laser system maker Cynosure (Westford, MA) has received expanded FDA approval to market its SculpSure hyperthermic laser treatment for noninvasive lipolysis of the abdomen. In May 2015, the FDA cleared the treatment for noninvasive lipolysis of the flanks.

Related: Cynosure hyperthermic laser treatment for noninvasive fat reduction receives FDA approval

SculpSure works to reduce fat noninvasively by disrupting subcutaneous fat cells. The hands-free device features a flexible applicator system to treat multiple anatomical areas of the body. The device, which uses a 1060 nm laser, can treat an anatomical area in approximately 25 minutes, allowing patients to achieve desired results without downtime or surgery.

The technology is expected to be launched in the U.S. in the second half of 2015.

Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)